Product Classification & Regulatory Assessment

Healthcare product regulation across the UAE and GCC is governed by overlapping classification frameworks, risk-based categorisation systems, and authority-specific registration pathways. A pharmaceutical product classified incorrectly under DOH or DHA requirements can trigger rejected applications, forced reclassifications, extended review cycles, and significant commercial losses, particularly for organisations managing multi-product portfolios across multiple emirates.

Alpha Health Group provides end-to-end product classification and regulatory assessment services that address these risks at source. Our consultants conduct detailed product reviews against current classification criteria established by UAE regulatory authorities, including the Ministry of Health and Prevention (MOH), the Department of Health Abu Dhabi (DOH), and the Dubai Health Authority (DHA). We evaluate intended use, mechanism of action, risk profile, and applicable regulatory pathway to determine accurate classification before submission.

Our regulatory assessment extends beyond classification into compliance gap analysis, documentation readiness evaluation, and registration strategy development. For medical device manufacturers, we map products against risk classification tiers (Class I through Class IV) and identify the regulatory route, technical file requirements, and post-market obligations specific to each jurisdiction. For pharmaceutical companies, we assess product dossier readiness against current registration guidelines and recommend corrective measures before authority submission.

Alpha Health Group reduces classification errors and shortens registration timelines for organisations entering or expanding in UAE and GCC healthcare markets.